Induced Pluripotent Stem Cells: Challenges and Opportunities

Authors

  • Ahmad Reza Bahrami Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Asiyeh Heirani Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Hamid Reza Bidkhori Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Hojjat Naderi Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Mahdi Mir-Ahmadi Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Mahmood Raees-Al-Mohaddesin Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Maliheh Hasan Zadeh Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Maryam M. Matin Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Mina Shahriari Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Moein Farshchian Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Saeideh Nakhaei Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Zahra Hejazi Cell and Molecular Biotechnology Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Abstract:

Regenerative capacity of mammals is limited and can rarely regenerate a specific organ or tissue fully. Due to these limitations, regenerative medicine seeks efficient and safe cell sources for regeneration of damaged tissues and organs or treatment for incurable diseases. Human embryonic stem cells (HESCs) hold two important properties called self renewal and pluripotency. However, the use of embryonic pluripotent stem cells in cell therapy faces two major obstacles. First, immunological incompatibility of ES cells with the recipient, and the second, ethical concerns about the destruction of human embryos during the ES cells. Thus, induction of somatic cells of individuals can be a proper way to overcome these problems. So far, several methods have been utilized to induce Pluripotency in Somatic cells. One of these methods is the technology of induced pluripotent stem cells (iPS) in contribution with Pluripotency factors. Yet, the use of these cells in the clinic, owing to application of viral vectors to transfer Pluripotency inducing factors, is quite limited. Therefore, recognition of a combination of small molecules to be replaced with exogenous factors is the ultimate goal of the study for the purpose of generating iPS cells. Recent progresses in development of iPS cells will be discussed here.   Keywords: IPS, Plupotency, Repair, Regeneration, Stem Cell.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

induced pluripotent stem cells: challenges and opportunities

regenerative capacity of mammals is limited and can rarely regenerate a specific organ or tissue fully. due to these limitations, regenerative medicine seeks efficient and safe cell sources for regeneration of damaged tissues and organs or treatment for incurable diseases. human embryonic stem cells (hescs) hold two important properties called self renewal and pluripotency. however, the use of ...

full text

Induced pluripotent stem cells: opportunities and challenges.

Somatic cells have been reprogrammed into pluripotent stem cells by introducing a combination of several transcription factors, such as Oct3/4, Sox2, Klf4 and c-Myc. Induced pluripotent stem (iPS) cells from a patient's somatic cells could be a useful source for drug discovery and cell transplantation therapies. However, most human iPS cells are made by viral vectors, such as retrovirus and len...

full text

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy

Despite recent advances in cancer treatment over the past 30 years, therapeutic options remain limited and do not always offer a cure for malignancy. Given that tumor-associated antigens (TAA) are, by definition, self-proteins, the need to productively engage autoreactive T cells remains at the heart of strategies for cancer immunotherapy. These have traditionally focused on the administration ...

full text

Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges.

Coronary artery disease with associated myocardial infarction continues to be a major cause of death and morbidity around the world, despite significant advances in therapy. Patients who have large myocardial infarctions are at highest risk for progressive heart failure and death, and cell-based therapies offer new hope for these patients. A recently discovered cell source for cardiac repair ha...

full text

Present and future challenges of induced pluripotent stem cells.

Growing old is our destiny. However, the mature differentiated cells making up our body can be rejuvenated to an embryo-like fate called pluripotency which is an ability to differentiate into all cell types by enforced expression of defined transcription factors. The discovery of this induced pluripotent stem cell (iPSC) technology has opened up unprecedented opportunities in regenerative medic...

full text

Induced pluripotent stem cells.

Reprogramming of mouse and human somatic cells into induced pluripotent stem (iPS) cells has been possible with retroviral expression of the pluripotency-associated transcription factors Oct4, Sox2, Nanog, and Lin28 as well as Klf4 and c-Myc. iPS cells hold great potential as a model for diseases from the perspective of the individual patient and as an alternative source of pluripotent stem cel...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue 2.3

pages  13- 13

publication date 2014-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023